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ABSTRACT 
Medicated Chewing Gums are mobile drug delivery systems. It is a potentially useful means of administering drugs either locally or systemically 
via, the oral absorption. The medicated chewing gum has through the years gained increasing acceptance as a drug delivery system. e.g. Aspirin 
as  an analgesic, Chlorhexidine as local disinfectant, Fluoride for prophylaxis of dental caries, Nicotine for smoking cessation, Caffeine as a stay 
alert preparation and Dimenhydrinate as antiemetic drugs etc. MCGs are solid, single dose preparations with a base consisting mainly of gums 
that are intended to be chewed but not swallowed. They contain one or more active substances which are released by chewing and are intended 
to be used for local treatment of mouth diseases or systemic delivery after absorption through the buccal mucosa and improve the oral 
bioavailability of drugs undergoing first pass metabolism. 
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INTRODUCTION 
Nausea means feeling "sick to the stomach", a sensation that 
is associated with the urge to vomit. Vomiting, the forceful 
discharge of gastric contents may be a protective physiologic 
mechanism that prevents entry of potentially harmful 
substances into the gastrointestinal tract. Persistent 
vomiting can lead to dehydration, severe alkalosis, bleeding 
and rarely esophageal perforation -- irrespective of the cause 
of vomiting1-2. 
Vomiting is to be differentiated from retching, regurgitation 
or rumination. Retching or dry heaves involves the same 
physiological mechanisms as vomiting, but occurs against a 
closed glottis; there is no expulsion of gastric contents. 
Regurgitation is the return of small amounts of food or 
secretions to the hypo pharynx in the context of mechanical 
obstruction of the esophagus, gastro esophageal reflux 
disease or esophageal motility disorders3-7. 
Medicated Chewing Gum (MCG) is a novel drug delivery 
system containing masticatory gum base with 
pharmacologically active ingredient and intended to use for 
local treatment of mouth diseases or systemic absorption 
through oral mucosa. The introduction and subsequent 
success of nicotine chewing gum in the 1980s paved the way 
for a more general acceptance of chewing gum as a drug 
delivery system8-12. Chewing gum delivery system is 
convenient, easy to administer anywhere, anytime and is 
pleasantly tasting making it patient acceptable. Medicated 
chewing gum offers a wide range of advantages that make it 
an excellent alternative. 
The medicated gums are dosage forms given orally for both 
local and therapeutic effect. It also offers the possibility of 
rapidly absorbing the drug through the oral mucosa leading 
to fast onset of action and bioavailability13-16. Also, it has 
superior sensorial properties compared with other dosage 
forms; it has a more attractive appeal and offers the patient 
an active control over the treatment. Drug absorbed directly 
via the buccal membrane avoids metabolism in the GI tract 
and the first-pass effect of the liver; it might therefore be to 
administer a reduce dose in chewing gum Compared to other 
oral delivery system. 
The dosage form offers many advantages like: 
 Convenient – promoting higher compliance. 
 Administration without water can be taken anywhere. 
 Advantageous for patients with difficulty in swallowing 
tablets. 
 Pleasant taste. 
 Counteracts dry mouth: Through stimulation of the 
salivary secretion thereby preventing Candidacies and 
Agrawal et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):43-47   
ISSN: 2250-1177                                                                                  [44]                                                                                 CODEN (USA): JDDTAO  
caries. 
 Highly acceptable by children. 
Active substances are released from medical chewing gum 
during chewing and are dissolved in saliva. The release rate 
can be carefully controlled through the formulation of the 
chewing gum allowing extended exposure in the oral cavity. 
Consequently, a lower dosage of substance may be 
therapeutically sufficient, possibly resulting in a fewer side 
effects, and promote fast absorption. Aspirin, 
Dimenhydrinate and Caffeine shows faster absorption 
through MCG than tablets, Stimulates flow of saliva in the 
mouth, Helps whiten teeth by reducing and preventing 
stains. The approach of this study was to design a chewing 
gum where the complete release of the drug dose from the 
formulation can be detected from an organoleptic change of 
the gum (in this case, the loss of a color) independently of 
the different chewing times and chewing frequency of the 
patients. Here, synthetic polymer is used as a base for 
chewing gum with different plasticizer, sweetener, colorants, 
fillers etc. for that we have to study some evaluation 
parameters like, release of drug in saliva, urinary excretion 
profile of drug, buccal absorption test. The main aim of this 
study is to reduce the vomiting frequency by enhancing its 
bioavailability and to by-pass its hepatic first pass 
metabolism. 
Granisetron hydrochloride 
Granisetron hydrochloride is a potent, selective antagonist of 
5- HT3 receptors. The antiemetic activity of the drug is 
brought about through the inhibition of 5-HT3 receptors 
present both centrally (medullary chemoreceptor zone) and 
peripherally (GI tract) 19-20. 
MATERIALS AND METHODS  
Materials 
Granisetron hydrochloride was received as a gift sample 
from. Sorbitol, Di-butyl phthalate, Glycerin, Talc, Sucrose and 
Peppermint flavor were of pharma grade and synthetic gum 
base from kamco chew foods and all other materials used 
were of the best possible Laboratory Reagent (LR) grade. 
Method of preparation 
Each gradient weighed accurately. Synthetic gum base and  
wax was melted to this molten mass , previously weighed 
quantity of plasticizer was added and then mixed thoroughly, 
the melting carried out in a porcelain dish at about 85-90°C 
on  steam bath.  This mixture allowed to cool at temperature 
of 35-45° C then the physical homogenous mixture of 
granisetron hydrochloride,  talc and sucrose was added with 
continuous stirring so that to ensure even distribution of 
drug. Then add flavor and color at the end of mixing. Then 
the mass was allowed to cool at room temperature in plastic 
moulds and weighed pieces are removed and wrapped 
properly (Table I) 
 
Table I: Different formulations and their ratios of ingredients 
S. No Ingredients 
Percentage 
MCG I MCG II MCG III MCG IV 
1 Synthetic gum base 25 35 45 55 
2 Drug 1% 1% 1% 1% 
3 Sorbitol 14.6 14.6 14.6 14.6 
4 Sucrose 1% -- -- 1% 
5 Flavor 0.6 0.6 0.6 0.6 
6 Magnesium stearate 0.2 0.2 0.2 0.2 
7 Talc 2.364 2.364 2.364 2.364 
8 Color Q.S Q.S Q.S Q.S 
 
Evaluation Parameters: 
Physical evaluation of synthetic gum base: The results of 
various test carried out for studying the properties of 
synthetic gum base and formulations are reported on the 
basis of their color, softening characters, relative humidity, 
moisture absorption, solubility studies in different solvents. 
Weight variation: weight of the ten chewing gums is taken 
in a one batch then average weight is calculated from that 
standard deviation is calculated. 
Hardness / Plasticity: Due to absence of any reported 
method,   it was decided to use the Monsanto type hardness 
tester for determination of hardness / plasticity of  all  MCG  
formulations. 
In-vitro drug release: All the formulation was studied for 
in- vitro drug release and the cumulative % of drug release 
was calculated. In-vitro release of drug was done by method 
described in experimental work. 
Stickiness: The MCG placed on the plain surface, mass of 
250 gm Teflon hammer collide on it for period of ten minute. 
The frequency of hammering was about 30 / minute. After 
10 minutes, sticking of mass to the hammered surface was 
observed and reported. 
Stability studies of synthetic gum base: 10 gm of synthetic 
gum base was stored in bottle at 50º C for 30 days. After 30 
days the gum was examined for natural ageing and physical 
nature. 
Release of drug in saliva:  
The drug release process from medicated chewing gum is 
quite different compared to a conventional oral drug 
delivery system, in fact; in this case, not only the dosage form 
but also the chewing activity of the patient may influence 
drug delivery. Gums are not intended to 
dissolve/disintegrate by themselves but a mechanical 
treatment of the dosage form is required to cause the drug to 
be delivered. For these reasons, the European 
Pharmacopoeia guidelines suggest the employment of a 
specific apparatus for gum formulations which simulates 
human chewing behavior.  To overcome all these difficulties, 
alternative solutions have been proposed19, 20, 21 the most 
accessible and obvious approach is to ask to a panel 
volunteers to chew the drug delivery device for a certain 
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period of time and to assess the remaining quantity of active 
substance in the residual gum. In this way, the gums are 
really chewed and the formulation is subjected not only to 
the mechanical stresses of an artificial machine but it also 
undergo all the phenomena involved in this process 
(increase of salivary secretion, saliva pH variation, 
swallowing and absorption by the oral mucosa, etc.) which 
can strongly influence the performance of the dosage form 
and the amount and rate of drug release. 
Optimized formulation with good consistency was selected 
for the release of drug in saliva. Four human volunteers were 
selected (two male and two female). Volunteers were 
instructed to rinse their mouth with distilled water and 
allowed to chewing the medicated granisetron hydrochloride 
chewing gum for 15 minutes, so that it’s maximum release 
has to be taken. Sample of saliva was taken after the 5 
minutes and then intervals were 2, 4, 6, 8, 10, 12, 14, 15 min. 
The saliva sample was made diluted in the phosphate buffer 
pH 6.8 and absorbance was analyzed at 301 nm by UV 
spectrophotometric method against reagent blank. 
Buccal absorption test: It was done by introducing 25 ml of 
drug solution of concentration about 5 mg / ml at different 
pH value of 1.2, 5, 6, 6.5, 7, 7.5, 7.8, 8, in the oral cavity of 
human volunteer who swirled it for 15 min and then 
expelled out. The expelled saliva was analyzed   at 301 nm by 
UV spectrophotometric method against blank reagent. 
RESULTS AND DISCUSSION 
Melting point: The melting point of the granisetron 
hydrochloride was found to be in the range of 290- 292 °C. It 
means the drug used is a pure one. Identification test: The λ 
max for granisetron hydrochloride was found to be 301 nm 
in the medium in the phosphate buffer having pH 6.8.  
Physicochemical properties of synthetic gum: Softening 
range of synthetic gum base is suitable for formulation of 
medicated chewing gum. Moisture absorption studies of 
synthetic gum: Synthetic gum base absorbs very less % of 
moisture means gum base is stable during shelf life. 
Solubility studies of synthetic gum: Solubility study of 
synthetic gum shows the sample of gum shows 1% solubility 
in alcohol. As the synthetic gum shows very minor amount 
soluble in phosphate buffer this value was as negligible so 
that taken in account so that synthetic gum was to be found 
to be best suited as chewing gum base in the formulation of 
MCGs. The synthetic gum shows insoluble nature in which 
gain boost for use in MCGs and confirms the insoluble nature 
of gum base. Stickiness of the all formulations was found 
negligible and hardness was found within the limit. Weight 
variations of all formulations were also found satisfactory. 
Drug content uniformity was between 93 to 96% that is 
within the normal range. Weight variations were also within 
the normal range. In-vitro drug release: From the study it 
was found that drug release of all formulations after 15 
minute were more than 55 %. These findings proposed a 
longer oral presence of granisetron hydrochloride in oral 
cavity. The graph shows the comparative drug study of all 
formulations in 20 minute. From the above study it was 
found that formulation “B” shows better release than other 
formulation. It concluded that formulation “B “was selected 
as best batch and carried out for his stability study. Drug 
release in saliva: From study it was found that drug release 
from all formulation after 14 minute was more than 40 %. In 
this study the drug release was depends upon the chewing 
frequency of the volunteer. From the study it was found that 
formulation “B” which we select as a best batch shows better 
release than other formulation in 14 minute. 
Stability studies of synthetic gum base: The stability study of 
synthetic gum base confirms the stability of gum during the 
process of ageing. There was no change in physical 
appearance and color of stored sample of synthetic gum 
base. There was change in the softening point of gum which 
confirms stability of synthetic gum base. 
 
Table 2: Physicochemical Properties of Synthetic Gum Base after Stability Studies 
S. No. Properties Observation 
1 Color (before ageing) Off white- pale yellow 
2 Color (after ageing) Off white- pale yellow 
3 Softening range (before ageing) 85-90°C 
4 Softening range (after ageing) 85-90°C 
 
Table 3: Texture Analysis data of Medicated Chewing Gum of Granisetron HCl 
S. No. 
Formulation 
Code 
Texture Analysis Data 
Hardness (Mean Max 
Force) (g) 
Firmness 
    (Mean Max Force) (g) 
Springiness 
   Mean Ratio (%) 
1 MCG I 3.515±0.24 966.3±0.81 7.414±0.12 
2 MCG II 2.163±0.07 931.6±0.66 7.332±0.14 
3 MCG III 2.095±0.04 787.8±0.20 7.123±0.23 
4 MCG IV 1.676±0.34 684.6±0.87 7.014±0.34 
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 Figure 1: Hardness test graph of various Medicated Chewing Gum formulation of Granisetron Hydrochloride MCG I (A), 
MCG II (B), MCG III (C), MCG IV (D) 
 
A                                             B 
Figure 2: Firmness and Springiness of Medicated Chewing Gum of Granisetron Hydrochloride: MCG I (A), MCG II (B) 
 
A                                                 B 
Figure 3: Firmness and Springiness of Medicated Chewing Gum of Granisetron Hydrochloride: MCG III (A), MCG IV (B) 
Agrawal et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2018; 8(6-A):43-47   
ISSN: 2250-1177                                                                                  [47]                                                                                 CODEN (USA): JDDTAO  
Table 4: Content Uniformity of Formulation 
S. No. Formulation % Purity 
1 A 95.68 
2 B 97.85 
3 C 93.65 
4 D 92.45 
 
 
Figure 4: % cumulative drug release for different MCGs 
formulations 
CONCLUSION 
Results of in-vitro release profile indicated that formulation 
“B” was the most promising formulation as the extent and 
steady release of drug from formulation was high as 
compare to other formulations. Infra-red spectroscopy 
shows the characteristics of the drug. Stability study 
conducted on medicated chewing gum for best formulation 
“B” under stress conditions for one month. Medicated 
chewing gum were evaluated for physical parameter as in-
vitro release after stability study, shows no significant 
changes were found in the parameters studied thus it could 
be concluded that formulation was fairly stable. A modified 
in-vitro drug release apparatus has been fabricated by 
modification of the IP disintegration test apparatus. Various 
Gum formulations with different composition were used to 
demonstrate the versatility of the chewing apparatus during 
study. When the in-vitro and  in-  vitro drug release results 
were compared, the drug release patterns in-vitro were 
fairly steady as compared to in-vitro and also less amount of 
drug has been released in equivalent  time  in vivo salivary 
drug release case. The vitro clinching apparatus needs bit 
further modifications for steady and relatively similar drug 
release match up to vivo drug release pattern. It can be 
concluded that in concentration of 50% synthetic gum base 
give promising results with the water soluble drug 
Granisetron Hydrochloride for steady drug release coupled 
with adequate release properties from medicated chewing 
gum. Some of the promising agents may incorporate in 
medicated chewing gum for improving the drug release from 
medicated chewing gum. The dissolution curves for the 
release of Granisetron Hydrochloride from the medicated 
chewing gum formulations are showed a satisfactory release 
rate. An explanation for this can be proposed by examining 
the drug release profiles of the gums. Synthetic gum 
formulations are similar marketed medicated chewing gum 
in appearance. Since synthetic gum base has 50% gum 
base used to formulate MCG compared to market medicated 
chewing gum this should provide a more pleasant mouth feel 
and it was expected that this would result in a steady and 
controlled release of drug. 
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